The Eastern European Cancer Market Outlook to 2010

Executive Summary

The countries of the Eastern European region feature a range of diverse healthcare systems, but can be divided into two categories, those of the EU accession countries which feature the strongest prospects for growth in pharmaceutical sales, and those of the post-communist countries which feature slow growth for original branded products. Across the twelve Eastern European countries, 97,168 women developed breast cancer in 2004. Across the twelve Eastern European markets, prostate cancer developed in 31,898 men in 2004. 140,614 persons were estimated to have developed lung cancer in 2004 across the twelve Eastern European countries. It is the leading cause of cancer-related death in men and second only to breast cancer in women. Colorectal cancer has the second highest incidence numbers in the twelve Eastern European pharmaceutical markets, after lung cancer. An estimated 107,896 individuals developed the disease in 2004. Across the twelve Eastern European pharmaceutical markets, an estimated 28,255 men and women developed pancreatic cancer in 2004, with a prevalence of only 12,736, making it one of the deadliest malignancies. An estimated 23,236 women developed ovarian cancer and 57,973 developed uterine cancer in 2004 in the twelve Eastern European pharmaceutical markets. In 2004, an estimated 23,072 men and women developed leukemia and 19,892 developed lymphomas across the twelve Eastern European pharmaceutical markets.